


Searching News Database: fentanyl,
HSMN NewsFeed - 15 Apr 2026
Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes
Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes
HSMN NewsFeed - 31 Jul 2017
Immunalysis Receives FDA Clearance for SEFRIA(TM) Fentanyl Urine Drug Screening Test
Immunalysis Receives FDA Clearance for SEFRIA(TM) Fentanyl Urine Drug Screening Test
HSMN NewsFeed - 5 Dec 2011
INSYS Therapeutics Announces Addition of VP of Marketing to Commercial Team
INSYS Therapeutics Announces Addition of VP of Marketing to Commercial Team
HSMN NewsFeed - 2 Mar 2009
Orexo's AbstralTM Receives Two Further Large EU Market Approvals in France and Spain
Orexo's AbstralTM Receives Two Further Large EU Market Approvals in France and Spain
HSMN NewsFeed - 14 Apr 2008
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
HSMN NewsFeed - 10 Jan 2008
FDA Accepts for Filing the BEMA(TM) Fentanyl NDA from BioDelivery Sciences
FDA Accepts for Filing the BEMA(TM) Fentanyl NDA from BioDelivery Sciences
HSMN NewsFeed - 27 Dec 2007
Endo Pharmaceuticals to Develop and Commercialize Alexza's AZ-003 Staccato(R) Inhaled Fentanyl Product
Endo Pharmaceuticals to Develop and Commercialize Alexza's AZ-003 Staccato(R) Inhaled Fentanyl Product
HSMN NewsFeed - 17 Dec 2007
Endo Announces Positive Results From Interim Analysis of RAPINYL(TM) Phase III Clinical Trial
Endo Announces Positive Results From Interim Analysis of RAPINYL(TM) Phase III Clinical Trial
HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
HSMN NewsFeed - 13 Sep 2007
Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
HSMN NewsFeed - 5 Sep 2007
BDSI Secures U.S. Commercial Partnership for BEMA(TM) Fentanyl with Meda AB
BDSI Secures U.S. Commercial Partnership for BEMA(TM) Fentanyl with Meda AB
HSMN NewsFeed - 14 Aug 2007
BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research
BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research
HSMN NewsFeed - 9 Aug 2007
Paladin And Glide Pharma Sign Exclusive Agreement for Novel Needle-Free Drug Delivery System
Paladin And Glide Pharma Sign Exclusive Agreement for Novel Needle-Free Drug Delivery System
HSMN NewsFeed - 21 Jun 2007
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
HSMN NewsFeed - 14 May 2007
BDSI Announces Positive Key Secondary Efficacy Endpoint Results for BEMA(TM) Fentanyl
BDSI Announces Positive Key Secondary Efficacy Endpoint Results for BEMA(TM) Fentanyl
HSMN NewsFeed - 25 Apr 2007
BDSI Announces Positive Phase III Clinical Trial Results for BEMA(TM) Fentanyl
BDSI Announces Positive Phase III Clinical Trial Results for BEMA(TM) Fentanyl
HSMN NewsFeed - 26 Mar 2007
Cephalon Files Marketing Application for Approval of a Fentanyl Effervescent Buccal Tablet in Europe
Cephalon Files Marketing Application for Approval of a Fentanyl Effervescent Buccal Tablet in Europe
HSMN NewsFeed - 30 Jan 2007
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer
HSMN NewsFeed - 9 Jan 2007
Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
HSMN NewsFeed - 8 Jan 2007
Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
HSMN NewsFeed - 20 Jul 2006
YM BioSciences reports anti-EGFr drug nimotuzumab approved in India for treatment of head and neck cancer
YM BioSciences reports anti-EGFr drug nimotuzumab approved in India for treatment of head and neck cancer
HSMN NewsFeed - 23 May 2006
ALZA Corporation Receives FDA Approval for IONSYS(TM) (Fentanyl Iontophoretic Transdermal System)
ALZA Corporation Receives FDA Approval for IONSYS(TM) (Fentanyl Iontophoretic Transdermal System)
Additional items found! 36
Members Archive contains
36 additional stories matching:
fentanyl,
(Password required)
fentanyl,
(Password required)
